Physician profile
Vanessa Abrina
NPI 1649577495
$6,909.46
in general payments reported to CMS, 2019-2025
40 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,843 · 2020: $557 · 2021: $734 · 2022: $1,260 · 2023: $1,541 · 2024: $873 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.87 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,314.70 | 2019-2024 | Vraylar, Linzess, Qulipta |
| Astrazeneca Pharmaceuticals LP | $952.83 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $623.68 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $541.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $494.76 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $376.01 | 2019-2023 | Eliquis |
| Novo Nordisk INC | $367.10 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $305.53 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $220.00 | 2019-2023 | Belsomra, Steglatro |
| Lilly USA, LLC | $217.67 | 2019-2024 | Emgality, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.61 | 2019-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $131.72 | 2022 | |
| Indivior INC. | $118.44 | 2019-2023 | Sublocade |
| Janssen Pharmaceuticals, INC | $110.52 | 2019-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $109.48 | 2023-2024 | Rexulti |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Abrina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.